Sofinnova Investments as of Dec. 31, 2018
Portfolio Holdings for Sofinnova Investments
Sofinnova Investments holds 58 positions in its portfolio as reported in the December 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Ascendis Pharma A S (ASND) | 12.2 | $94M | 1.5M | 62.65 | |
| Amarin Corporation (AMRN) | 9.2 | $71M | 5.2M | 13.61 | |
| Obseva Sa | 7.8 | $60M | 4.7M | 12.66 | |
| Principia Biopharma | 7.3 | $56M | 2.0M | 27.39 | |
| Natera (NTRA) | 5.6 | $43M | 3.1M | 13.96 | |
| Y Mabs Therapeutics (YMAB) | 5.6 | $43M | 2.1M | 20.34 | |
| Nucana Plc american depositary shares (NCNA) | 4.3 | $33M | 2.3M | 14.50 | |
| Merus N V (MRUS) | 3.6 | $28M | 2.0M | 14.00 | |
| Coherus Biosciences (CHRS) | 3.4 | $26M | 2.9M | 9.05 | |
| Kiniksa Pharmaceuticals (KNSA) | 3.4 | $26M | 923k | 28.09 | |
| Audentes Therapeutics | 2.6 | $20M | 934k | 21.32 | |
| Spark Therapeutics | 2.5 | $19M | 481k | 39.14 | |
| Sanofi-Aventis SA (SNY) | 1.9 | $14M | 327k | 43.41 | |
| Aclaris Therapeutics (ACRS) | 1.8 | $14M | 1.9M | 7.39 | |
| Gilead Sciences (GILD) | 1.7 | $13M | 213k | 62.54 | |
| BioMarin Pharmaceutical (BMRN) | 1.6 | $12M | 141k | 85.16 | |
| Incyte Corporation (INCY) | 1.6 | $12M | 189k | 63.60 | |
| AstraZeneca (AZN) | 1.6 | $12M | 316k | 37.98 | |
| Tesaro | 1.3 | $10M | 134k | 74.24 | |
| Heron Therapeutics (HRTX) | 1.2 | $9.3M | 360k | 25.94 | |
| Reata Pharmaceuticals Inc Cl A | 1.1 | $8.9M | 158k | 56.10 | |
| Iterum Therapeutics | 1.1 | $8.6M | 1.7M | 5.01 | |
| Morphosys (MPSYF) | 1.1 | $8.2M | 81k | 102.01 | |
| Rigel Pharmaceuticals (RIGL) | 1.0 | $7.8M | 3.4M | 2.30 | |
| Xencor (XNCR) | 0.9 | $7.2M | 200k | 36.17 | |
| Amicus Therapeutics (FOLD) | 0.8 | $6.5M | 675k | 9.58 | |
| Savara (SVRA) | 0.7 | $5.7M | 754k | 7.57 | |
| Deciphera Pharmaceuticals (DCPH) | 0.7 | $5.6M | 266k | 20.98 | |
| Intercept Pharmaceuticals In | 0.7 | $5.5M | 55k | 100.84 | |
| Sarepta Therapeutics (SRPT) | 0.7 | $5.3M | 49k | 109.19 | |
| Clovis Oncology | 0.7 | $5.2M | 288k | 17.95 | |
| Chiasma | 0.7 | $5.1M | 1.6M | 3.11 | |
| Entasis Therapeutics Holdings Ord | 0.6 | $4.8M | 1.2M | 4.07 | |
| Neurocrine Biosciences (NBIX) | 0.6 | $4.4M | 62k | 71.46 | |
| Macrogenics (MGNX) | 0.6 | $4.2M | 333k | 12.70 | |
| Aimmune Therapeutics | 0.6 | $4.2M | 176k | 23.92 | |
| Synlogic | 0.5 | $4.0M | 575k | 7.01 | |
| Puma Biotechnology (PBYI) | 0.5 | $3.9M | 191k | 20.35 | |
| Dermira | 0.5 | $3.9M | 542k | 7.19 | |
| Fibrogen (FGEN) | 0.5 | $3.7M | 80k | 46.30 | |
| Biohaven Pharmaceutical Holding | 0.5 | $3.6M | 97k | 37.01 | |
| Orchard Therapeutics Plc ads | 0.5 | $3.5M | 223k | 15.74 | |
| Epizyme | 0.5 | $3.5M | 564k | 6.16 | |
| Kadmon Hldgs | 0.5 | $3.4M | 1.7M | 2.08 | |
| Foamix Pharmaceuticals | 0.4 | $3.0M | 832k | 3.59 | |
| Gw Pharmaceuticals Plc ads | 0.4 | $2.9M | 30k | 97.37 | |
| Five Prime Therapeutics | 0.4 | $2.9M | 315k | 9.30 | |
| Fate Therapeutics (FATE) | 0.4 | $2.9M | 230k | 12.82 | |
| ImmunoGen | 0.3 | $2.1M | 447k | 4.80 | |
| Kala Pharmaceuticals | 0.3 | $2.2M | 446k | 4.88 | |
| Osmotica Pharmaceuticals (RVLPQ) | 0.3 | $2.0M | 253k | 7.75 | |
| Otonomy | 0.2 | $1.9M | 1.0M | 1.85 | |
| Anaptysbio Inc Common (ANAB) | 0.2 | $1.6M | 25k | 63.68 | |
| Syndax Pharmaceuticals (SNDX) | 0.2 | $1.6M | 350k | 4.46 | |
| Conatus Pharmaceuticals | 0.1 | $1.1M | 638k | 1.73 | |
| Edge Therapeutics | 0.1 | $913k | 2.9M | 0.32 | |
| Pacira Pharmaceuticals (PCRX) | 0.1 | $730k | 17k | 42.94 | |
| Apellis Pharmaceuticals (APLS) | 0.1 | $654k | 50k | 13.19 |
